高级检索
    王秀, 刘真, 吴晶晶, 王秀丽, 乌日娜. 人附睾蛋白4、CA199、LPA在卵巢癌中的表达及与临床病理特征的相关性[J]. 蚌埠医科大学学报, 2021, 46(2): 183-186, 190. DOI: 10.13898/j.cnki.issn.1000-2200.2021.02.012
    引用本文: 王秀, 刘真, 吴晶晶, 王秀丽, 乌日娜. 人附睾蛋白4、CA199、LPA在卵巢癌中的表达及与临床病理特征的相关性[J]. 蚌埠医科大学学报, 2021, 46(2): 183-186, 190. DOI: 10.13898/j.cnki.issn.1000-2200.2021.02.012
    shu
    WANG Xiu, LIU Zhen, WU Jing-jing, WANG Xiu-li, WU Ri-na. Expression of human epididymal protein 4, CA199 and LPA in ovarian cancer, and its correlation with clinicopathological features[J]. Journal of Bengbu Medical University, 2021, 46(2): 183-186, 190. DOI: 10.13898/j.cnki.issn.1000-2200.2021.02.012
    Citation: WANG Xiu, LIU Zhen, WU Jing-jing, WANG Xiu-li, WU Ri-na. Expression of human epididymal protein 4, CA199 and LPA in ovarian cancer, and its correlation with clinicopathological features[J]. Journal of Bengbu Medical University, 2021, 46(2): 183-186, 190. DOI: 10.13898/j.cnki.issn.1000-2200.2021.02.012
    shu

    人附睾蛋白4、CA199、LPA在卵巢癌中的表达及与临床病理特征的相关性

    Expression of human epididymal protein 4, CA199 and LPA in ovarian cancer, and its correlation with clinicopathological features

      摘要
    • 摘要:
      目的探究人附睾蛋白4（HE4）、糖类抗原199（CA199）、人溶血磷脂酸（LPA）在卵巢癌中的表达及与临床病理特征的相关性。
      方法选择卵巢癌病人140例作为卵巢癌组，同期选取因卵巢良性病变而行手术切除的病人120例作为卵巢良性病变组，并择同期行健康体检女性100名作为健康对照组。检测3组研究对象HE4、CA199、LPA水平，比较HE4、CA199、LPA在卵巢良性病变组与卵巢癌组卵巢组织中的阳性表达情况，分析HE4、CA199、LPA与卵巢癌病人临床病理特征的相关性，HE4、CA199、LPA之间的相关性。
      结果血清HE4、CA199、血浆LPA水平，卵巢癌组血清均高于卵巢良性病变组和健康对照组，卵巢良性病变组均高于健康对照组（P < 0.05）；HE4、CA199、LPA在卵巢癌组卵巢组织中的阳性表达率均高于卵巢良性病变组（P < 0.01）。HE4、CA199、LPA表达与卵巢癌病人病理类型、肿瘤直径无相关性（P>0.05）；与卵巢癌病人临床分期、分化程度、有无淋巴结转移有相关性（P < 0.01），其中临床分期Ⅲ~Ⅳ期、低分化程度、有淋巴结转移的病人HE4、CA199、LPA表达水平较高。HE4与CA199之间呈正相关（r=0.183, P < 0.05），HE4与LPA之间呈正相关（r=0.216, P < 0.05），CA199与LPA之间呈正相关（r=0.209, P < 0.05）。
      结论HE4、CA199、LPA在卵巢癌病人中为高表达，且与病人临床分期、分化程度、有无淋巴结转移相关。

       

      Abstract:
      ObjectiveTo study the correlations among the expression levels of human epididymal protein 4(HE4), carbohydrate antigen 199(CA199) and human lysophosphatidic acid(LPA) in ovarian cancer, and its clinicopathological features.
      MethodsOne hundred and forty patients with ovarian cancer, 120 ovarian benign lesions patients treated with operation and 100 healthy women were divided into the ovarian cancer group, ovarian benign lesion group and healthy control group, respectively.The expression levels of HE4, CA199 and LPA in three groups were detected, the positive expression of HE4, CA199 and LPA between ovarian benign lesion group and ovarian cancer group were compared.The correlation of the HE4, CA199 and LPA with clinicopathological characteristics of ovarian cancer patients, and correlation among the expression of HE4, CA199 and LPA were analyzed.
      ResultsThe serum levels of HE4, CA199 and plasma LPA in ovarian cancer group were higher than those in benign ovarian lesion group and healthy control group(P < 0.05), and the positive rates of HE4, CA199 and LPA in ovarian cancer group were higher than those in benign ovarian lesion group(P < 0.01).The expression levels of HE4, CA199 and LPA were not correlated with the pathological type and diameter of ovarian cancer(P>0.05), but which were related to the clinical stage, differentiation degree and lymph node metastasis of ovarian cancer patients(P < 0.01).The expression levels of HE4, CA199 and LPA in patients with stage Ⅲ-Ⅳ, low differentiation and lymph node metastasis were higher.The HE4 level was positively correlated with CA199(r=0.183, P < 0.05), the HE4 level was positively correlated with LPA(r=0.216, P < 0.05), and the CA199 level was positively correlated with LPA(r=0.209, P < 0.05).
      ConclusionsThe expression levels of HE4, CA199 and LPA in ovarian cancer patients are high, which are related to the clinical stage, differentiation degree and lymph node metastasis.

       

      • HTML全文
      • 参考文献(19)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回